Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Aeterna Zentaris
Thumbnail
November 01, 2018

Flipping for the win at Strongbridge Biopharma

Strongbridge's deal with Novo Nordisk over Macrilen tops up the former's cash pile and pays off debt just 10 months after the company licensed the project from Aeterna Zentaris.

December 08, 2017

Upcoming events – Aeterna’s second try and Pharmamar’s ovarian data

Vantage logo
May 05, 2017

Snippet roundup: Novartis's allogeneic CAR-T drive and Astra's IL-4 interest

Vantage logo
November 11, 2016

Upcoming events – Corbus leans on Resunab and crunch time for Aeterna’s Macrilen

Vantage logo
June 17, 2016

Upcoming events – Phase III data for plecanatide and Zoptrex

Vantage logo
March 17, 2016

Revisiting a predictor of failure in the post-Celator world

Vantage logo
January 07, 2016

The biotech whip-rounds start early

Vantage logo
September 08, 2014

Therapeutic focus – AbbVie endorses the bull case for PI3K inhibition

Vantage logo
July 22, 2014

Small-molecule launches hold their own

Vantage logo
September 03, 2013

Therapeutic focus – Big pharma adds weight to thin cachexia pipeline

Vantage logo
July 04, 2012

Obesity turnaround drives small cap gainers in H1

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up